This website has been developed and is being maintained on behalf of ESFRI by the StR-ESFRI project which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement n° 654213
A new development pathway for translating novel biological insights into effective solutions
The European Advanced Translational Research Infrastructure in Medicine (EATRIS) is a distributed RI that provides a unique one-stop shop access to the combined expertise and high-end technologies, required to develop new products for translational medicine, from target validation to early clinical trials. By selecting several key resources in Europe, users can access to research tools and guidance required for drug development, ranging from state-of-the-art scientific equipment, knowledge-based resources from sample collections to GMP manufacturing and regulatory guidance. Services and access to patient cohorts are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.
EATRIS received the status of European Research Infrastructure Consortium (ERIC) in November 2013. It comprises 90 leading institutes in 13 countries – 12 Members and 1 Observer – that represent the wide diversity of stakeholders who seek solutions to the many issues arising in the development of new therapies.
By bringing together Europe’s best institutions in academic translational medicine, EATRIS has created a portfolio of research services focused on predicting the performance of novel products, selecting the right patient, and entering clinical development as safely and effectively as possible. On the basis of a detailed database and knowledge of its growing member institutions, EATRIS quickly matches the users’ needs with the right expertise and facilities to build project teams along technology pipelines and supporting services, running from target/biomarker validation up to clinical proof of concept, covering the following areas: Advanced Therapy Medicinal Products (ATMP) and biologics – including Gene Therapy Medicinal Products (GTMP), Cell Therapy Medicinal Products (CTMP), and Tissue Engineered Products (TEP) - represent a new category of medicines with a wide therapeutic potential for treating different types of diseases such as cancer, neurodegenerative and cardiovascular diseases; Small Molecules, to support the pre-clinical and clinical development of drug candidates, utilising academic expertise around novel targets; Vaccines, to cover the entire vaccine development and production pipeline ranging from late-phase pre-clinical development to clinical trials.
These pipelines are supported by cutting edge enabling technologies: Imaging and Tracing, to provide a single point of entry to high-end expertise and cutting-edge translational imaging facilities, defragmenting the technical know-how and making optimal use of resources to improve R&D output; Biomarkers for precision medicine, to facilitate the validation and development of biomarkers for the prevention, diagnosis and prognostic assessment of disease as well as for the prediction of therapy response.
In order to ensure that each project has a comprehensive team and best chance of success, EATRIS also offers regulatory support, as well as education and training opportunities in translational research.
Improving the output of scientific discoveries into innovative and high impact medicines, diagnostics and medical devices will have a considerable socio-economic impact in Europe and globally, especially in the long-term. The wide range of interest of EATRIS, that extends also to rare and neglected diseases and includes personalised medicine, is expected to give a general improvement in the drug discovery process leading to the development of innovative solutions, also aimed at patient groups. EATRIS acts as a forum for open debate between the three sectors – academic community, industry and the public – in order to improve communication, legal and regulatory alignment and competitiveness, and reduce uncertainty for the practitioners of translational science. Also, by encouraging training in translational science, EATRIS supports the long-term sustainability of the discipline, and will facilitate further innovation by providing the next generations of top international talent.
Amsterdam, The Netherlands